Sarepta Therapeutics disclosed that a patient being treated for Duchenne muscular dystrophy with Elevidys passed away from acute liver failure, causing the company's shares to drop by 23%. The pharmaceutical company acknowledged that acute liver injury was a potential side effect of Elevidys and similar gene therapies, though it was the first death reported while on the drug. The patient had recently experienced a cytomegalovirus infection, which the treating physician identified as a possible contributing factor to the liver failure. Sarepta is currently examining the incident and has alerted health authorities, intending to update its prescribing information accordingly. Investopedia has reached out to Sarepta for further insights into potential actions following the event. With today's significant decline, Sarepta Therapeutics' stock has depreciated by over 35% in the past year.